Connect with us
Merck, a science and technology company, generated strong net sales growth in the second quarter of 2019, primarily on an organic basis. EBITDA pre grew very...
Lonza reported continued positive momentum in its core healthcare businesses in the first six months of 2019. This has driven 6.4% sales and 7.7% CORE EBITDA...
Merck, a science and technology company, and the Broad Institute of MIT and Harvard (Boston, Massachusetts) announced an agreement to offer non-exclusive licenses to CRISPR intellectual...
Engineers and designers are always looking for solutions to make their and our life easier. Especially in our times, which are characterized by high cost pressure...
The new conical tube format of 25 mL, developed by the inventor of the “Eppi” tube, will advance the world of conical tubes. Working with sample...
Lonza announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third antibody-drug-conjugate (ADC) produced at...
Merck, a science and technology company, announced that its proposed transaction with Intermolecular, was approved by the stockholders of Intermolecular at a special meeting held on...
Filter solutions provide are an important cornerstone of hygienic production environments, as required in the pharmaceutical and other process industries. Filter solutions often lead a niche...
Merck, a science and technology company, today successfully placed bonds amounting to € 2.0 billion. The placement is a component of the financing of the planned...
Following the news that the FDA has approved Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis; “Dupixent is the first biologic to be approved...
